Edwards Lifesciences Corp... (EW)
| Bid | 75.16 |
| Market Cap | 44.25B |
| Revenue (ttm) | 5.54B |
| Net Income (ttm) | 4.18B |
| EPS (ttm) | 2.38 |
| PE Ratio (ttm) | 31.74 |
| Forward PE | 27.39 |
| Analyst | Hold |
| Ask | 76.1 |
| Volume | 2,472,270 |
| Avg. Volume (20D) | 4,793,006 |
| Open | 76.58 |
| Previous Close | 75.18 |
| Day's Range | 75.42 - 77.12 |
| 52-Week Range | 58.93 - 95.25 |
| Beta | 1.15 |
About EW
Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases. The company also provides the P...
Analyst Forecast
According to 20 analyst ratings, the average rating for EW stock is "Hold." The 12-month stock price forecast is $79, which is an increase of 4.57% from the latest price.
Stock ForecastsEarnings Surprise
2 weeks ago · businesswire.com
Eight-Year Data Confirm Long-Term Durability of Edwards' RESILIA TissueCAIRO--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today announced new eight-year data showing that patients receiving aortic surgical valves treated with its proprietary RESILIA tissue technolog...
